Clinical trial
Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
NCT03823352 is registered in ClinicalTrials.gov with Golden Biotechnology Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
- Lead sponsor
- Golden Biotechnology Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 20, 2019
- Completion date
- December 31, 2020
- Enrollment
- 12 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.